Compare KDK & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KDK | MYGN |
|---|---|---|
| Founded | 2018 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 335.0M | 372.1M |
| IPO Year | 2023 | 1996 |
| Metric | KDK | MYGN |
|---|---|---|
| Price | $1.30 | $6.08 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 9 |
| Target Price | ★ $9.67 | $4.49 |
| AVG Volume (30 Days) | ★ 5.8M | 2.9M |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | $3,797,000.00 | ★ $771,400,000.00 |
| Revenue This Year | $181.17 | N/A |
| Revenue Next Year | $208.63 | $5.47 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2.33 |
| 52 Week Low | $0.96 | $2.74 |
| 52 Week High | $11.35 | $8.09 |
| Indicator | KDK | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 41.64 | 61.46 |
| Support Level | $0.96 | $4.15 |
| Resistance Level | $1.43 | $6.49 |
| Average True Range (ATR) | 0.13 | 0.42 |
| MACD | 0.07 | -0.01 |
| Stochastic Oscillator | 71.87 | 53.29 |
Kodiak AI Inc is a provider of artificial intelligence (AI)-powered autonomous vehicle technology. This technology addresses the needs of the long-haul trucking, industrial trucking, and defense industries. The company's core offering, the Kodiak Driver, is a single-platform virtual driver that combines advanced AI software with modular hardware for customer deployments. All company operations are conducted in the United States. The company has one operating and reportable segment related to the development of autonomous vehicle technology and related services that can be applied at scale across a broad range of industries and environments.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.